Progyny, Inc. $PGNY Stock Holdings Boosted by State of Alaska Department of Revenue

State of Alaska Department of Revenue lifted its position in Progyny, Inc. (NASDAQ:PGNY) by 8.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,425 shares of the company’s stock after buying an additional 3,376 shares during the period. State of Alaska Department of Revenue owned approximately 0.05% of Progyny worth $976,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Progyny in the first quarter worth about $44,000. Militia Capital Partners LP acquired a new position in shares of Progyny in the 1st quarter worth approximately $45,000. Brooklyn Investment Group raised its holdings in shares of Progyny by 5,216.4% in the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company’s stock worth $72,000 after purchasing an additional 3,182 shares in the last quarter. GAMMA Investing LLC lifted its stake in Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock valued at $120,000 after purchasing an additional 3,768 shares during the last quarter. Finally, AlphaQuest LLC lifted its stake in Progyny by 57.9% during the first quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock valued at $127,000 after purchasing an additional 2,079 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PGNY shares. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research report on Saturday, September 27th. Leerink Partners upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price on the stock in a report on Tuesday, July 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price target on Progyny in a research report on Friday, August 8th. Finally, Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Progyny has a consensus rating of “Moderate Buy” and a consensus target price of $25.44.

Insider Activity

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares of the company’s stock, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the transaction, the director owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,895 shares of company stock valued at $179,311 in the last three months. 9.40% of the stock is owned by insiders.

Progyny Stock Up 0.2%

NASDAQ:PGNY opened at $20.59 on Monday. The company’s 50 day moving average is $22.59 and its 200-day moving average is $22.26. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 34.90, a P/E/G ratio of 1.75 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The firm had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.